Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesenchymal stem cell therapy in hospitalized patients with COVID-19 and acute pulmonary insufficiency
IRCT20190717044241N3Phase 2Completed
- Sponsor
- Barkat Pharmaceutical Group
- Start
- Dec 2020
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2 trial of mesenchymal stem cells in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Barkat Pharmaceutical Group. Primary endpoints: Clinical response, Oxygen saturation and 2 more. Started Dec 2020; status: completed.
02
Drugs
mesenchymal stem cells
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20190717044241N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190717044241N3.